Similar articles

• Prostate-specific antigen and prostate cancer prognosis.

  Church TR. Church TR. J Natl Cancer Inst. 2006 Nov 1;98(21):1509-10. doi: 10.1093/jnci/djj455. J Natl Cancer Inst. 2006. PMID: 17077347 No abstract available.
• What to do with an abnormal PSA test.

  Loeb S, Catalona WJ. Loeb S, et al. Oncologist. 2008 Mar;13(3):299-305. doi: 10.1634/theoncologist.2007-0139. Oncologist. 2008. PMID: 18378540 Review.
• Prostate cancer screening; is this a teachable moment?

  Brawley OW. Brawley OW. J Natl Cancer Inst. 2009 Oct 7;101(19):1295-7. doi: 10.1093/jnci/djp310. Epub 2009 Aug 31. J Natl Cancer Inst. 2009. PMID: 19720970 No abstract available.
• Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

  Hamilton RJ, Platz EA, Freedland SJ. Hamilton RJ, et al. J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7. J Natl Cancer Inst. 2009. PMID: 19351913 No abstract available.
• Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.

  Ito K. Ito K. Int J Urol. 2009 May;16(5):458-64. doi: 10.1111/j.1442-2042.2009.02293.x. Epub 2009 Apr 1. Int J Urol. 2009. PMID: 19341365 Review.